Loading...
XMAD
CBAV
Market cap578mUSD
Apr 07, Last price  
32.50EUR
1D
-0.91%
1Q
-1.81%
Jan 2017
242.11%
Name

Clinica Baviera SA

Chart & Performance

D1W1MN
No data to show
P/E
13.18
P/S
2.02
EPS
2.47
Div Yield, %
4.83%
Shrs. gr., 5y
-0.03%
Rev. gr., 5y
16.13%
Revenues
263m
+16.77%
43,396,64763,527,04278,381,63287,936,70783,141,22489,682,81493,592,99989,880,51979,975,65082,620,56385,527,35291,572,17699,879,659109,293,546124,333,421122,625,591172,730,250198,449,250224,923,951262,648,000
Net income
40m
+11.77%
9,378,896-26,285,570-23,666,4287,011,5781,860,8355,239,0395,403,828-87,5874,886,6494,054,8894,879,7167,914,4209,770,09611,826,23712,794,64713,941,69727,389,52729,518,52835,970,92840,205,000
CFO
63m
+8.56%
015,753,36419,538,92610,262,7058,106,31114,445,15614,526,8938,086,34210,221,3899,664,72610,838,74413,545,58415,831,36416,813,73225,402,08631,455,53046,856,58853,377,07257,812,11562,762,000
Dividend
Jul 16, 20241.57 EUR/sh
Earnings
May 22, 2025

Profile

Clínica Baviera, S.A., a medical company, operates a network of ophthalmology clinics. The company is involved in the diagnosis, treatment, and monitoring of various types of visual disorders. Its clinics offers myopia, hyperopia, astigmatism, presbyopia, cataract, retina, pediatric ophthalmology, glaucoma, squint, cornea, neuroftalmología, vías lagrimales, and oculoplasty treatments. It operates approximately 90 centers in Spain, Germany, Austria, and Italy. The company is based in Madrid, Spain.
URL
https://www.clinicabaviera.com/
IPO date
Jan 01, 2000
Employees
1,423
Domiciled in
ES
Incorporated in
ES

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
262,648
16.77%
224,924
13.34%
198,449
14.89%
Cost of revenue
30,565
53,236
53,708
Unusual Expense (Income)
NOPBT
232,083
171,688
144,741
NOPBT Margin
88.36%
76.33%
72.94%
Operating Taxes
14,855
12,919
10,533
Tax Rate
6.40%
7.52%
7.28%
NOPAT
217,228
158,769
134,208
Net income
40,205
11.77%
35,971
21.86%
29,519
7.77%
Dividends
(25,890)
(13,042)
(17,188)
Dividend yield
5.10%
3.48%
6.02%
Proceeds from repurchase of equity
(8,809)
5
(20)
BB yield
1.73%
0.00%
0.01%
Debt
Debt current
10,655
2,006
Long-term debt
81,368
73,385
Deferred revenue
Other long-term liabilities
61,979
3,972
2,464
Net debt
(12,534)
40,690
52,890
Cash flow
Cash from operating activities
62,762
57,812
53,377
CAPEX
(26,508)
(22,679)
(14,031)
Cash from investing activities
(20,899)
(44,313)
(12,559)
Cash from financing activities
(39,910)
(24,366)
(31,446)
FCF
193,626
145,789
125,382
Balance
Cash
38,581
51,241
38,990
Long term investments
(26,047)
93
(16,489)
Excess cash
40,087
12,579
Stockholders' equity
43,276
87,165
93,086
Invested Capital
160,339
103,431
96,285
ROIC
164.71%
159.00%
134.00%
ROCE
143.92%
119.20%
132.64%
EV
Common stock shares outstanding
16,277
16,303
16,303
Price
31.20
35.65%
23.00
31.43%
17.50
-17.45%
Market cap
507,853
35.44%
374,961
31.43%
285,303
-17.45%
EV
496,759
416,930
339,217
EBITDA
252,963
188,668
159,738
EV/EBITDA
1.96
2.21
2.12
Interest
1,217
572
419
Interest/NOPBT
0.52%
0.33%
0.29%